BABYLON PUMP & POWER LIMITED — Capital/Financing Update 2008

Jun 11, 2008

June 12, 2008

�������������������������

��������������������������

IM MEDICAL FINALISES SIGMA DEAL FOR RETAIL ROLLOUT OF INTELLIHEART

IM Medical today announced an agreement to sell the Intelliheart cardiac risk assessment tests through one of Australia’s biggest retail health networks.

Under an exclusivity agreement signed this week, Sigma Pharmaceuticals Ltd will purchase the unique Intelliheart tests and sell them in hundreds of Amcal Max , Amcal and Guardian pharmacies around Australia.

The Chief Executive Officer of IM Medical, Mr Tommas Bonvino, said the agreement was a significant milestone in IM Medical’s commercialisation strategy for Intelliheart.

“The alliance combines IM Medical’s risk assessment technology leadership with the powerful brands and marketing power of Sigma,” he said.

“This combination will make preventative medicine a reality for more people. Cardiovascular disease is Australia’s number one health issue measured by deaths and health costs. Much of it can be prevented. The first step is measuring risk and that it where Intelliheart comes in.”

Sales through the Sigma network are expected to begin through more than 200 pharmacies in Victoria in July, with other States following in the next few months.

Intelliheart is a superior, non-invasive cardiac risk assessment test which takes a number of measurements for doctors to analyse and measure cardiac risk. It is the only widely available test which tests heart rate variability and arterial stiffness, two tests which research is showing are powerful new indicators of possible heart problems.

Sigma is one of Australia’s biggest manufacturers, distributors and marketers of pharmaceutical products. Its national network includes more than 700 retail pharmacies under the Amcal and Guardian banners.

==> picture [595 x 93] intentionally omitted <==

……..2

2

==> picture [595 x 94] intentionally omitted <==

Under the agreement, Sigma will also have the right to produce and market other health and heart-related products under the Intelliheart brand.

The exclusivity agreement with Sigma follows a successful pilot program in a number of pharmacies where consumer acceptance was tested and demonstrated.

Mr Bonvino said the agreement cemented Intelliheart’s entry to the retail market. Intelliheart was introduced in medical practices in 2006. In the past 12 months, it has become available in workplace testing programs and a national network of fitness centres.

The Managing Director of Sigma Pharmaceuticals, Mr Elmo de Alwis, said: “Sigma is delighted to be involved in this important health care initiative. Prevention is the easiest, most inexpensive and best cure for cardiovascular disease and this alliance will bring the prospect of prevention closer to the patients. The positioning of our retail banners, Amcal Max , Amcal and Guardian, lends themselves to the community based activities which rely on the pharmacists professional advisory role ".

Intelliheart uses specialised equipment and software to measure blood pressure, heart rate variability, blood vessel stiffness and the electrical activity of the heart. These measurements are combined with other data such as cholesterol levels, blood glucose levels, family history, smoking history, lifestyle and weight to assess a patient’s risk of heart problems.

Further information: CEO Tommas Bonvino 9860 0900 Media enquiries: Michael Smith 0411 055 306

==> picture [595 x 94] intentionally omitted <==

==> picture [595 x 93] intentionally omitted <==